| Trial | control | p<0.05 | harm | NS |
|---|
| ENDEAVOR, 2016 | carfilzomib vs bortezomib | OS 0.79 [0.65; 0.96] median 47.6 mo vs. 40.0 mo PFS 0.53 [0.44; 0.64] median 18.7 mo vs. 9.4 mo | | |
| ASPIRE, 2014 | carfilzomib lenalidomide dexamethasone vs lenalidomide and dexamethasone alone | OS 0.79 [0.63; 0.99] PFS 0.69 [0.57; 0.83] median 26.3 mo vs. 17.6 mo | | |
| FOCUS, 2017 | carfilzomib vs low-dose corticosteroids | | | OS 0.98 [0.76; 1.25] median 10.2 mo vs. 10.0 mo |
| ECOG-ACRIN | carfilzomib vs bortezomid | | | |
| CLARION | carfilzomib vs bortezomid | | | |
| Trial | Treatments | Patients | Method |
|---|
| ENDEAVOR, 2016 | carfilzomib with dexamethasone (n=464) vs. bortezomib with dexamethasone (n=465) | patients with relapsed or refractory multiplemyeloma who had one to three previous treatments | open-label Sample size: 464/465 Primary endpoint: PFS FU duration: |
| ASPIRE, 2014 | carfilzomib with lenalidomide and dexamethasone (n=-9) vs. lenalidomide and dexamethasone alone (n=-9) | patients with relapsed multiple myeloma | open-label Sample size: -9/-9 Primary endpoint: PFS FU duration: |
| FOCUS, 2017 | carfilzomib monotherapy (n=157) vs. low-dose corticosteroids and optional cyclophosphamide (n=158) | relapsed and refractory multiple myeloma (RRMM) | open-label Parallel groups Sample size: 157/158 Primary endpoint: OS FU duration: |
| ECOG-ACRIN | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| CLARION | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
